Adverse Uses and Effects of Gemcitabine

Department of Chemistry, Imam Khomeini International University, Iran

Editorial

Gemci abine i ili ed in di eren carcinoma . I i ili ed a a r - line herap alone for pancrea ic malignanc and in mi i h ci - pla in for c ing edge or me a a ic bladder di ea e and progre ed or me a a ic non- li le cell cell lar breakdo n in he l ng . I i ili ed a a econd- line herap in blend i h carbopla in for o arian malignanc and in mi i h pacli a el for che infec ion ha i me a a ic or can be deci i el aken o . Since i i clinicall igni can and i j al - able hen con e ed in ra eno l echniq e o reform la e i o i end o be gi en b mo h ha e been a bjec of e plora ion.

In e iga ion in o pharmacogenomic and pharmaco- gene ic ha been con in o . S ar ing a 2014, i a no a i fac or he her he- redi ar e co ld be helpf l in managing do ing and hich indi id - al reac be o gemci abine. o i h anding, apparen l arie in he o o of pro ein SLC29A1, SLC29A2, SLC28A1, and SLC28A3) ili ed for ran por of gemci abine in o he cell lead o arie ie in i reng h. Al o, he q ali ie ha e pre pro ein ha lead o i inac i - a ion deo c idine deamina e, c idine deamina e, and T5C) and ha e pre i o her in racell lar arge RRM1, RRM2, and RRM2B) lead o arie ie beca e of he medica ion. E amina ion ha addi ion- all been con in o o ee ho ran forma ion in pancrea ic mo r hem el e decide reac ion o gemci abine. I ha been read a a herap for Kapo i arcoma, a pical malignanc in indi id al i h AI S

Mohammadreza Khanmohammadi, Department of Chemistry, Imam Khomeini International University, Iran, E-mail: mohammad.k@gmail.com

November 06, 2020; November 20, 2020; November 27, 2020

Gemcitabine.J Cancer Diag 4: 2.